Adverse Effects of Antipsychotics

Clinical Trials in Psychopharmacology: A Better Brain: Second Edition

Volumn , Issue , 2010, Pages 337-380

  Landry, Pierre ^a   Rousseau, Anne Marie ^b   Skalli, Leila ^c  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adverse effects of antipsychotics; Antipsychotic effects on prolactinemia, bone mineral density (BMD) and water osmosis; Antipsychotics similar efficacy for treating psychotic symptoms; Antipsychotics, binding affinity to dopamine D2 receptors; Atypical antipsychotics (AAs) and conventional antipsychotics (CAs); Basal ganglia neurons sustaining motor behaviors modified by antipsychotic medication; Obsessive compulsive symptoms (OCSs) emergence or exacerbation; Orthostatic hypotension, blood pressure and pulse variations; Sexual dysfunction, recognized as a very inconvenient side effect; Syndrome of inappropriate secretion of antidiuretic hormone or SIADH

Indexed keywords

EID: 84886003462     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470749180.ch17     Document Type: Chapter

References (190)

1. Lieberman, J.A., Stroup, T.S., McEvoy, J.P. et al. (2005) Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators: effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353, 1209-1223.
2. Shim, J.C., Choe, B.M., Kim, J.G. et al. (2007) Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis. Journal of Clinical Psychopharmacology, 27 (4), 400-401.
3. Mjorndal, T., Boman, M.D., Hagg, S. et al. (2002) Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiology and Drug Safety, 11 (1), 65-72.
4. Pirmohamed, M., James, S., Meakin, S. et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. British Medical Journal, 329 (7456), 15-19.
5. Wester, K., Jonsson, A.K., Spigset, O. et al. (2008) Incidence of fatal adverse drug reactions: a population based study. British Journal of Clinical Pharmacology, 65 (4), 573-579.
6. Meltzer, H.Y., Matsubara, S., and Lee, J.C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. Journal of Pharmacology and Experimental Therapeutics, 251 (1), 238-246.
7. Seeman, P. (2002) Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry: Revue Canadienne de Psychiatrie, 47 (1), 27-38.
8. Preskorn, S.H. (2004) Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions (part II). Journal of Psychiatric Practice, 10 (3), 177-181.
9. Nasrallah, H.A. (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Molecular Psychiatry, 13 (1), 27-35.
10. Smith, M., Hopkins, D., Peveler, R.C. et al. (2008) First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry, 192 (6), 406-411.
11. Bagnall, A.M., Jones, L., Ginnelly, L. et al. (2003) A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assessment (Winchester, England), 7 (13), 1-193.
12. Gao, K., Kemp, D.E., Ganocy, S.J. et al. (2008) Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. Journal of Clinical Psychopharmacology, 28 (2), 203-209.
13. Friedman, J.H. (2003) Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocrinology, 28 (Suppl 1), 39-51.
14. Browne, S., Roe, M., Lane, A. et al. (1996) Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica Scandinavica, 94 (2), 118-124.
15. Ballesteros, J., Gonzalez-Pinto, A., and Bulbena, A. (2000) Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. Journal of Clinical Psychopharmacology, 20 (2), 188-194.
16. Kane, J.M., Woerner, M., Weinhold, P. et al. (1984) Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacology Bulletin, 20 (3), 387-389.
17. Glazer, W.M., Morgenstern, H., and Doucette, J.T. (1993) Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. Journal of Clinical Psychiatry, 54 (4), 133-139.
18. Jeste, D.V., Caligiuri, M.P., Paulsen, J.S. et al. (1995) Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Archives of General Psychiatry, 52 (9), 756-765.
19. Woerner, M.G., Alvir, J.M., Saltz, B.L. et al. (1998) Prospective study of tardive dyskinesia in the elderly: rates and risk factors. The American Journal of Psychiatry, 155 (11), 1521-1528.
20. Jeste, D.V. (2000) Tardive dyskinesia in older patients. Journal of Clinical Psychiatry, 61 (Suppl 4), 27-32.
21. Kane, J.M. (1999) Tardive dyskinesia in affective disorders. Journal of Clinical Psychiatry, 60 (Suppl 5), 43-47; discussion 8-9.
22. van Harten, P.N., Hoek, H.W., Matroos, G.E. et al. (2006) Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curacao extrapyramidal syndromes study V. Journal of Clinical Psychiatry, 67 (12), 1920-1927.
23. Sachdev, P. (2004) Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Australian and New Zealand Journal of Psychiatry, 38 (6), 445-449.
24. Tenback, D.E., van Harten, P.N., Slooff, C.J. et al. (2006) Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. The American Journal of Psychiatry, 163 (8), 1438-1440.
25. Correll, C.U. and Schenk, E.M. (2008) Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry, 21 (2), 151-156.
26. Lee, P.E., Sykora, K., Gill, S.S. et al. (2005) Antipsychotic medications and druginduced movement disorders other than parkinsonism: a population-based cohort study in older adults. Journal of the American Geriatrics Society, 53 (8), 1374-1379.
27. de Leon, J. (2007) The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. European Archives of Psychiatry and Clinical Neuroscience, 257 (3), 169-172.
28. Lieberman, J.A., Saltz, B.L., Johns, C.A. et al. (1991) The effects of clozapine on tardive dyskinesia. The British Journal of Psychiatry, 158, 503-510.
29. Kinon, B.J., Jeste, D.V., Kollack-Walker, S. et al. (2004) Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28 (6), 985-996.
30. Emsley, R., Turner, H.J., Schronen, J. et al. (2004) A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry, 65 (5), 696-701.
31. Lerner, V., Miodownik, C., Kaptsan, A. et al. (2007) Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. The Journal of Clinical Psychiatry, 68 (11), 1648-1654.
32. Soares, K.V. and McGrath, J.J. (2001) Vitamin E for neuroleptic-induced tardive dyskinesia. [update of Cochrane Database Systematic Reviews 2000;(2):CD000209; PMID: 10796508]. Cochrane Database of Systematic Reviews 4 (Art No.: CD000209).
33. Hardoy, M.C., Carta, M.G., Carpiniello, B. et al. (2003) Gabapentin in antipsychoticinduced tardive dyskinesia: results of 1-year follow-up. Journal of Affective Disorders, 75 (2), 125-130.
34. Paleacu, D., Giladi, N., Moore, O. et al. (2004) Tetrabenazine treatment in movement disorders. Clinical Neuropharmacology, 27 (5), 230-233.
35. Cunningham-Owens, D.G. (1999) A Guide to Extrapyramidal Side Effects of Antipsychotic Drugs, Cambridge University Press, Cambridge
36. Christodoulou, C. and Kalaitzi, C. (2005) Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review. Journal of Psychopharmacology, 19 (3), 307-311.
37. Mellacheruvu, S., Norton, J.W., and Schweinfurth, J. (2007) Atypical antipsychotic drug-induced acute laryngeal dystonia: 2 case reports. Journal of Clinical Psychopharmacology, 27 (2), 206-207.
38. Raja, M. and Azzoni, A. (2001) Novel antipsychotics and acute dystonic reactions. International Journal of Neuropsychopharmacology, 4 (4), 393-397.
39. Arana, G.W., Goff, D.C., Baldessarini, R.J. et al. (1988) Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. The American Journal of Psychiatry, 145 (8), 993-996.
40. Hennings, J.M.H., Krause, E., Botzel, K. et al. (2008) Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32 (5), 1167-1171.
41. Cohen, O.S., Hassin-Baer, S., and Spiegelmann, R. (2007) Deep brain stimulation of the internal globus pallidus for refractory tardive dystonia. Parkinsonism and Related Disorders, 13 (8), 541-544.
42. Sun, B., Chen, S., Zhan, S. et al. (2007) Subthalamic nucleus stimulation for primary dystonia and tardive dystonia. Acta Neurochirurgica: Supplement, 97 (Pt 2), 207-214.
43. Sachdev, P. (1994) Research diagnostic criteria for drug-induced akathisia: conceptualization, rationale and proposal. Psychopharmacology, 114 (1), 181-186.
44. Sachdev, P. (1995) The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Schizophrenia Bulletin, 21 (3), 451-461.
45. Bratti, I.M., Kane, J.M., and Marder, S.R. (2007) Chronic restlessness with antipsychotics. The American Journal of Psychiatry, 164 (11), 1648-1654.
46. Miller, C.H. and Fleischhacker, W.W. (2000) Managing antipsychotic-induced acute and chronic akathisia. Drug Safety, 22 (1), 73-81.
47. Keshavan, M.S., Prasad, K.M., Montrose, D.M. et al. (2007) Sleep quality and architecture in quetiapine, risperidone, or never-treated schizophrenia patients. Journal of Clinical Psychopharmacology, 27 (6), 703-705.
48. Luthringer, R., Staner, L., Noel, N. et al. (2007) A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. International Clinical Psychopharmacology, 22 (5), 299-308.
49. Miler Del, D. (2004) Atypical antipsychotics: sleep, sedation, and efficacy. Primary care companion to the Journal of clinical Psychiatry, 6 (2), 3-7.
50. Krystal, A.D., Goforth, H.W., and Roth, T. (2008) Effects of antipsychotic medications on sleep in schizophrenia. International Clinical Psychopharmacology, 23 (3), 150-160.
51. Baggaley, M. (2008) Sexual dysfunction in schizophrenia: focus on recent evidence. Human Psychopharmacology, 23 (3), 201-209.
52. Kelly, D.L. and Conley, R.R. (2004) Sexuality and schizophrenia: a review. Schizophrenia Bulletin, 30 (4), 767-779.
53. Labbate, L.A. (2008) Psychotropics and sexual dysfunction: the evidence and treatments. Advances in Psychosomatic Medicine, 29, 107-130.
54. Bobes, J., Garc A-Portilla, M.P., Rejas, J. et al. (2003) Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. Journal of Sex and Marital Therapy, 29 (2), 125-147.
55. Malik, P. (2007) Sexual dysfunction in schizophrenia. Current Opinion in Psychiatry, 20 (2), 138-142.
56. De Hert, M., Schreurs, V., Sweers, K. et al. (2008) Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophrenia Research, 101 (1-3), 295-303.
57. Martin-Du, P.R. and Baumann, P. (2008) [Sexual dysfunctions induced by antidepressants and antipsychotics]. Revue Medicale Suisse, 4 (150), 758-762.
58. Cavallaro, R., Cocchi, F., Angelone, S.M. et al. (2004) Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. Journal of Clinical Psychiatry, 65 (2), 187-190.
59. Michalopoulou, P.G. and Lykouras, L. (2006) Manic/hypomanic symptoms induced by atypical antipsychotics: a review of the reported cases. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30 (4), 549-564.
60. Rachid, F., Bertschy, G., Bondolfi, G. et al. (2004) Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. The Journal of Clinical Psychiatry, 65 (11), 1537-1545.
61. Baldacara, L., de Castro Ferrari,M.C., Monteiro, B.F. et al. (2007) Hypomania induced by atypical antipsychotics among schizophrenic patients: report of three cases. Pharmacopsychiatry, 40 (4), 169-170.
62. Erberk-Ozen, N. (2008) Manic symptoms probably associated with short-term low-dose quetiapine use. Advances in Therapy, 25, 53-57.
63. Jensen, N., Rodriguiz, R.M., Caron, M.G. et al. (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology, 33, 2303-2312.
64. de Haan, L., Beuk, N., Hoogenboom, B. et al. (2002) Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. The Journal of Clinical Psychiatry, 63 (2), 104-107.
65. Mahendran, R., Liew, E., and Subramaniam, M. (2007) De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study. The Journal of Clinical Psychiatry, 68 (4), 542-545.
66. Byerly, M., Goodman,W., Acholonu, W. et al. (2005) Obsessive compulsive symptoms in schizophrenia: frequency and clinical features. Schizophrenia Research, 76 (2-3), 309-316.
67. Lim, M., Park, D.Y., Kwon, J.S. et al. (2007) Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics. Journal of Clinical Psychopharmacology, 27 (6), 712-713.
68. Ertugrul, A., Anil Yagcioglu, A.E., Eni, N. et al. (2005) Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients. Psychiatry and Clinical Neurosciences, 59 (2), 219-222.
69. van Nimwegen, L., de Haan, L., van Beveren, N. et al. (2008) Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. Journal of Clinical Psychopharmacology, 28 (2), 214-218.
70. Newcomer, J.W. (2007) Metabolic syndrome and mental illness. American Journal of Managed Care, 13 (Suppl 7), S170-S177.
71. Malik, S., Wong, N.D., Franklin, S.S. et al. (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 110 (10), 1245-1250.
72. Weiden, P.J., Mackell, J.A., and McDonnell, D.D. (2004) Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research, 66 (1), 51-57.
73. Russell, J.M. and Mackell, J.A. (2001) Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs, 15 (7), 537-551.
74. Must, A., Spadano, J., Coakley, E.H. et al. (1999) The disease burden associated with overweight and obesity. The Journal of the American Medical Association, 282 (16), 1523-1529.
75. Rege, S. (2008) Antipsychotic induced weight gain in schizophrenia:mechanisms and management. Australian and New Zealand Journal of Psychiatry, 42 (5), 369-381.
76. Baptista, T., ElFakih, Y., Uzcategui, E. et al. (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs, 22 (6), 477-495.
77. Haddad, P. (2005) Weight change with antipsychotics in the treatment of schizophrenia. Journal of Pharmacology, 19 (Suppl 6), 17-27.
78. Newcomer, J.W. (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19 (Suppl 1), 1-93.
79. Haupt, D.W. (2006) Differential metabolic effects of antipsychotic treatments. European Neuropsychopharmacology, 16 (Suppl 3), S149-S155.
80. Allison, D., Mentore, L.J., and Hea, M. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. The American Journal of Psychiatry, 156, 1686-1696.
81. Alvarez-Jiménez, M., Gonzalez-Blanch, C., Crespo-Facorro, B. et al. (2008) Antipsychoticinduced weight gain in chronic and first-episode psychotic disorders. A systematic reappraisal. CNS Drugs, 22, 547-562.
82. Saddichha, S., Manjunatha, N., Ameen, S. et al. (2008) Diabetes and schizophrenia- effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatrica Scandinavica, 117 (5), 342-347.
83. American Diabetes A, American Psychiatric A, American Association of Clinical E, North American Association for the Study of O (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27 (2), 596-601.
84. Jin, H., Meyer, J.M., and Jeste, D.V. (2002) Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Annals of Clinical Psychiatry, 14 (1), 59-64.
85. Lindenmayer, J-P., Czobor, P., Volavka, J. et al. (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. The American Journal of Psychiatry, 160 (2), 290-296.
86. Henderson, D.C. (2005) Schizophrenia and comorbid metabolic disorders. Journal of Clinical Psychiatry, 66 (Suppl 6), 11-20.
87. Busche, C. and Paton, C. (2005) The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? Journal of Pharmacology, 19 (Suppl), 76-83.
88. Meyer, J.M. and Koro, C.E. (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research, 70 (1), 1-17.
89. McQuade, R.D., Stock, E., Marcus, R. et al. (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. The Journal of Clinical Psychiatry, 65 (Suppl 18), 47-56.
90. Cohn, T.A. and Sernyak, M.J. (2006) Metabolic monitoring for patients treated with antipsychotic medications. Canadian Journal of Psychiatry: Revue Canadienne de Psychiatrie, 51 (8), 492-501.
91. Casey, D.E., Haupt, D.W., Newcomer, J.W. et al. (2004) Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. Journal of Clinical Psychiatry, 65 (Suppl 7), 4-18; quiz 9-20.
92. Faulkner, G. and Cohn, T.A. (2006) Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. [erratum appears in Can J Psychiatry. 2006 Aug;51(9):620]. Canadian Journal of Psychiatry: Revue Canadienne de Psychiatrie, 51 (8), 502-511.
93. Poulin, M-J., Chaput, J-P., Simard, V. et al. (2007) Management of antipsychoticinduced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Australian and New Zealand Journal of Psychiatry, 41 (12), 980-989.
94. Faulkner, G., Cohn, T., and Remington, G. (2007) Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews 1 (Art. No.: CD005148).
95. Isakov, I., Klesmer, J., and Masand, P.S. (2000) Insulin-resistant hyperglycemia induced by clozapine. Psychosomatics, 41 (4), 373-374.
96. Landry, P., Dimitri, E., Tessier, S. et al. (2008) Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. Journal of Clinical Psychopharmacology, 28 (3), 348-349.
97. Ojala, K., Repo-Tiihonen, E., Tiihonen, J. et al. (2008) Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. Journal of Psychopharmacology, 22 (1), 33-38.
98. NCEP (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486-2497.
99. Lu, M-L., Lane, H-Y., Lin, S-K. et al. (2004) Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. The Journal of Clinical Psychiatry, 65 (6), 766-771.
100. Koponen, H., Alaraisanen, A., Saari, K. et al. (2008) Schizophrenia and sudden cardiac death: a review. Nord Journal Psychiatry, 62, 342-345.
101. Drici, M-D. and Priori, S. (2007) Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiology and Drug Safety, 16 (8), 882-890.
102. Iqbal, M.M., Aneja, A., Rahman, A. et al. (2004) Therapeutic options in the treatment of clozapine-induced adverse effects. Journal of Pharmacology, 20, 155-164.
103. Gupta, A., Lawrence, A.T., Krishnan, K. et al. (2007) Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. American Heart Journal, 153 (6), 891-899.
104. Justo, D., Prokhorov, V., Heller, K. et al. (2005) Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatrica Scandinavica, 111 (3), 171-176.
105. Stollberger, C., Huber, J.O., and Finsterer, J. (2005) Antipsychotic drugs and QT prolongation. International Clinical Psychopharmacology, 20 (5), 243-251.
106. Merrill, D.B., Dec, G.W., and Goff, D.C. (2005) Adverse cardiac effects associated with clozapine. Journal of Clinical Psychopharmacology, 25 (1), 32-41.
107. Rostagno, C., Di Norscia, G., Placidi, G.F. et al. (2008) Beta-blocker and angiotensin-converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine. General Hospital Psychiatry, 30 (3), 280-283.
108. Verhelst, J. and Abs R. (2003) Hyperprolactinemia: pathophysiology and management. Treat Endocrinol, 2 (1), 23-32.
109. Byerly, M., Suppes, T., Tran, Q-V. et al. (2007) Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. Journal of Clinical Psychopharmacology, 27 (6), 639-661.
110. Montejo, A.L. (2008) Prolactin awareness: an essential consideration for physical health in schizophrenia. European Neuropsychopharmacology, 18 (Suppl 2), S108-S114.
111. Meaney, A.M., Smith, S., Howes, O.D. et al. (2004) Effects of long term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. British Journal of Psychiatry, 184 (6), 503-508.
112. Haddad, P.M. andWieck, A. (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs, 64 (20), 2291-2314.
113. Sun, B., Fujiwara, K., Adachi, S. et al. (2005) Physiologiacal roles of prolacin-raising peptide. Regul Pept, 126 (1), 27-33.
114. Wang, P.S., Walker, A.M., Tsuang, M.T. et al. (2002) Dopamine antagonists and the development of breast cancer. Archives of General Psychiatry, 59 (12), 1147-1154.
115. Henderson, D.C. and Doraiswamy, P.M. (2008) Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. The Journal of Clinical Psychiatry, 69 (Suppl 1), 32-44.
116. Yuan, H-N., Wang, C-Y., Sze, C.W. et al. (2008) A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. Journal of Clinical Psychopharmacology, 28 (3), 264-370.
117. Halbreich, U. (2007) Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs, 21 (8), 641-657.
118. Siegel, A.J. (2008) Hyponatremia in psychiatric patients: update on evaluation and management. Harvard Review of Psychiatry, 16 (1), 13-24.
119. Kohen, I., Voelker, S., and Manu, P. (2008) Antipsychotic-induced hyponatremia: case report and literature review. American Journal of Therapeutics, 15 (5), 492-494.
120. Bersani, G., Pesaresi, L., Orlandi, V. et al. (2007) Atypical antipsychotics and polydipsia: a cause or a treatment? Human Psychopharmacology, 22 (2), 103-107.
121. Bralet, M-C., Ton, T., and Falissard, B. (2007) Schizophrenic patients with polydipsia and water intoxication more often have a form of schizophrenia first described by Kraepelin. Psychiatry Research, 152 (2-3), 267-271.
122. Alper, K., Schwartz, K.A., Kolts, R.L. et al. (2007) Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biological Psychiatry, 62 (4), 345-354.
123. Haddad, P.M. and Dursun, S.M. (2008) Neurological complications of psychiatric drugs: clinical features and management. Human Psychopharmacology, 23 (Suppl 1), 15-26.
124. Hedges, D., Jeppson, K., and Whitehead, P. (2003) Antipsychotic medication and seizures: a review. Drugs of Today, 39 (7), 551-557.
125. Koch-Stoecker, S. (2002) Antipsychotic drugs and epilepsy: indications and treatment guidelines. Epilepsia, 43 (Suppl 2), 19-24.
126. Wong, J. and Delva, N. (2007) Clozapine-induced seizures: recognition and treatment. Canadian Journal of Psychiatry: Revue Canadienne de Psychiatrie, 52 (7), 457-463.
127. Amann, B.L., Pogarell, O., Mergl, R. et al. (2003) EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects. Human Psychopharmacology, 18 (8), 641-646.
128. Centorrino, F., Price, B.H., Tuttle, M. et al. (2002) EEG abnormalities during treatment with typical and atypical antipsychotics. The American Journal of Psychiatry, 159 (1), 109-115.
129. Devinsky, O., Honigfeld, G., and Patin, J. (1991) Clozapine-related seizures. Neurology, 41 (3), 369-371.
130. Strawn, J.R., Keck, P.E. Jr, and Caroff, S.N. (2007) Neuroleptic malignant syndrome. The American Journal of Psychiatry, 164 (6), 870-876.
131. Sheil, A.T., Collins, K.A., Schandl, C.A. et al. (2007) Fatal neurotoxic response to neuroleptic medications: case report and review of the literature. American Journal of Forensic Medicine and Pathology, 28 (2), 116-120.
132. Ananth, J., Parameswaran, S., Gunatilake, S. et al. (2004) Neuroleptic malignant syndrome and atypical antipsychotic drugs. The Journal of Clinical Psychiatry, 65 (4), 464-470.
133. Adityanjee, A., Sajatovic, M., and Munshi, K.R. (2005) Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clinical Neuropharmacology, 28 (4), 197-204.
134. Reulbach, U., Dutsch, C., Biermann, T. et al. (2007) Managing an effective treatment for neuroleptic malignant syndrome. Critical Care (London, England), 11 (1), R4.
135. Holtmann, M., Meyer, A.E., Pitzer, M. et al. (2003) Risperidone-induced marked elevation of serum creatine kinase in adolescence. A case report. Pharmacopsychiatry, 36 (6), 317-318.
136. Perlov, E., Tebartz van Elst, L., Czygan, M. et al. (2005) Serum creatine kinase elevation as a possible complication of therapy with olanzapine. Naunyn-Schmiedebergs Archives of Pharmacology, 372 (2), 168-169.
137. Gaertner, I., Altendorf, K., Batra, A. et al. (2001) Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. Journal of Clinical Psychopharmacology, 21 (2), 215-222.
138. Selim, K. and Kaplowitz, N. (1999) Hepatotoxicity of psychotropic drugs. Hepatology, 29 (5), 1347-1351.
139. Macfarlane, B., Davies, S., Mannan, K. et al. (1997) Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology, 112 (5), 1707-1709.
140. Rettenbacher, M.A., Baumgartner, S., Eder-Ischia, U. et al. (2006) Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study. Journal of Clinical Psychopharmacology, 26 (5), 500-503.
141. Mouradian-Stamatiadis, L., Dumortier, G., Januel, D. et al. (2002) Liver function tests during treatment with antipsychotic drugs: a case series of 23 patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26 (7-8), 1409-1411.
142. Atasoy, N., Erdogan, A., Yalug, I. et al. (2007) A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31 (6), 1255-1260.
143. Dumortier, G., Cabaret, W., Stamatiadis, L. et al. (2002) Hepatic tolerance of atypical antipsychotic drugs. Encephale, 28 (6 Pt 1), 542-551.
144. Alvir, J.M., Lieberman, J.A., Safferman, A.Z. et al. (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. The New England Journal of Medicine, 329 (3), 162-167.
145. Atkin, K., Kendall, F., Gould, D. et al. (1996) Neutropenia and Agranulocytosis in patients receiving clozapine in the UK and Ireland. British Journal of Psychiatry, 169 (4), 483-488.
146. Kang, B.J., Cho, M.J., Oh, J.T., et al. (1993) Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS? Human Psychopharmacology, 21 (6), 387-391.
147. Munro, J., O'Sullivan, D., Andrews, C., et al. (1999) Active monitoring of 12760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. British Journal of Psychiatry, 175, 576-580.
148. Dunk, L.R., Annan, L.J., and Andrews, C.D. (2006) Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. The British Journal of Psychiatry, 188, 255-263.
149. Kanaan, R.A. and Kerwin, R.W. (2006) Lithium and clozapine rechallenge: a retrospective case analysis. The Journal of Clinical Psychiatry, 67 (5), 756-760.
150. Mihaljevic-Peles, A., Jakovljevic, M., Mrsic, M. et al. (2001) Thrombocytopenia associated with clozapine and fluphenazine. Nordic Journal of Psychiatry, 55 (6), 449-450.
151. Hampson, M.E. (2000) Clozapine-induced thrombocytosis. The British Journal of Psychiatry, 176, 400.
152. Raedler, T.J., Reimer, J., and Wiedemann, K. (2007) Dose-dependent constipation with higher doses of quetiapine: a case series. International Clinical Psychopharmacology, 22 (4), 244-246.
153. Palmer, S.E., McLean, R.M., Ellis, P.M. et al. (2008) Life-threatening clozapineinduced gastrointestinal hypomotility: an analysis of 102 cases. The Journal of Clinical Psychiatry, 69 (5), 759-768.
154. Lieberman, J.A. (2004) Managing anticholinergic side-effects. The Journal of Clinical Psychiatry, 6 (2), 20-23.
155. Mago, R., Chism, L.M., Pinninti, N.R. et al. (2008) Urinary retention associated with ziprasidone: a case report. The Journal of Clinical Psychiatry, 69 (3), 499-500.
156. Szabadi, E. and Tavernor, S. (1999) Hypo and hypersalivation induced by psychoactive drugs: incidence, mechanisms and therapeutic implications. CNS Drugs, 11, 449-466.
157. Prommer, E. (2005) Re: Olanzapine-induced delirium. Journal of Pain and Symptom Management, 29 (2), 119-120.
158. Shankar, B.R. (2008) Clozapine-induced delirium. Journal of Neuropsychiatry and Clinical Neurosciences, 20 (2), 239-240.
159. Hagg, S. and Spigset, O. (2002) Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs, 16 (11), 765-776.
160. Zornberg, G.L. and Jick, H. (2000) Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet, 356 (9237), 1219-1223.
161. Liperoti, R., Pedone, C., Lapane, K.L. et al. (2005) Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Archives of Internal Medicine, 165 (22), 2677-2682.
162. Walker, A.M., Lanza, L.L., Arellano, F., and Rothman, K.J. (1997) Mortality in current and former users of clozapine. Epidemiology, 8 (6), 671-677.
163. Jonsson, A.K., Brudin, L., Ahlner, J. et al. (2008) Antipsychotics associated with pulmonary embolism in a Swedish medicolegal autopsy series. International Clinical Psychopharmacology, 23 (5), 263-268.
164. Sacchetti, E., Trifiro, G., Caputi, A. et al. (2008) Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. Journal of Psychopharmacology, 22 (1), 39-46.
165. Kales, H.C., Valenstein, M., Kim, H.M. et al. (2007) Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. The American Journal of Psychiatry, 164 (10), 1568-1576; quiz 623.
166. Gill, S.S., Bronskill, S.E., Normand, S.-L.T. et al. (2007) Antipsychotic drug use and mortality in older adults with dementia. (Summary for patients in Ann Intern Med. 2007 Jun 5;146(11):I52; PMID: 17548405). Annals of Internal Medicine, 146 (11), 775-786.
167. Rochon, P.A., Normand, S.-L., Gomes, T. et al. (2008) Antipsychotic therapy and short-term serious events in older adults with dementia. Archives of Internal Medicine, 168 (10), 1090-1096.
168. Schneider, L.S., Dagerman, K., and Insel, P.S. (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry, 14 (3), 191-210.
169. Schneider, L.S., Tariot, P.N., Dagerman, K.S. et al. (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. The New England Journal of Medicine, 355 (15), 1525-1538.
170. Jeste, D.V., Blazer, D., Casey, D. et al. (2008) ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology, 33 (5), 957-970.
171. Waddington, J.L., Youssef, H.A., and Kinsella, A. (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. The British Journal of Psychiatry, 173, 325-329.
172. Modai, I., Hirschmann, S., Rava, A. et al. (2000) Sudden death in patients receiving clozapine treatment: a preliminary investigation. Journal of Clinical Psychopharmacology, 20 (3), 325-327.
173. Muller, N. and Schwarz, M.J. (2008) A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. European Archives of Psychiatry and Clinical Neuroscience, 258 (Suppl 2), 97-106.
174. Drzyzga, L., Obuchowicz, E., Marcinowska, A. et al. (2006) Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain, Behavior, and Immunity, 20 (6), 532-545.
175. Landry, P., Benaliouad, F., and Tessier, S. (2003) Increased use of antibiotics in clozapine-treated patients. International Clinical Psychopharmacology, 18 (5), 297-298.
176. Warnock, J.K. and Morris, D.W. (2002) Adverse cutaneous reactions to antipsychotics. American Journal of Clinical Dermatology, 3 (9), 629-636.
177. Freudenreich, O. (2005) Drug-induced sialorrhea. Drugs of Today, 41 (6), 411-418.
178. Praharaj, S.K., Arora, M., and Gandotra, S. (2006) Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology, 185 (3), 265-273.
179. Koller, E.A., Cross, J.T., Doraiswamy, P.M. et al. (2003) Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy, 23 (9), 1123-1130.
180. Gasse, C., Jacobsen, J., Pedersen, L. et al. (2008) Risk of hospitalization for acute pancreatitis associated with conventional and atypical antipsychotics: a population-based case-control study. Pharmacotherapy, 28 (1), 27-34.
181. Fornaro, P., Calabria, G., Corallo, G. et al. (2002) Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis. Documenta Ophthalmologica, 105 (1), 41-49.
182. Novais, E., Souza, V.B., De Moura Filho, F.J. et al. (2008) Cataract occurrence in patients treated with antipsychotic drugs. Revista Brasileira de Psiquiatrica, 30, 222-226.
183. Fraunfelder, F.W. (2004) Twice-yearly exams unnecessary for patients taking quetiapine. American Journal of Ophthalmology, 138 (5), 870-871.
184. Shahzad, S., Suleman, M-I., Shahab, H. et al. (2002) Cataract occurrence with antipsychotic drugs. Psychosomatics, 43 (5), 354-359.
185. Buckley, P.F. and Correll, C.U. (2008) Strategies for dosing and switching antipsychotics for optimal clinical management. The Journal of Clinical Psychiatry, 69 (Suppl 1), 4-17.
186. Seppala, N., Kovio, C., and Leinonen, E. (2005) Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. CNS Drugs, 19 (12), 1049-1055.
187. Moncrieff, J. (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica, 114 (1), 3-13.
188. Fernandez, H.H., Trieschmann, M.E., and Okun, M.S. (2005) Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease. Movement Disorders, 20 (1), 104-105.
189. Miodownik, C., Lerner, V., Kibari, A. et al. (2006) The effect of sudden clozapine discontinuation on management of schizophrenic patients: A retrospective controlled study. The Journal of Clinical Psychiatry, 67 (8), 1204-1208.
190. Gardner, D.M., Baldessarini, R.J., and Waraich, P. (2005) Modern antipsychotic drugs: a critical overview. Canadian Medical Association Journal, 172 (13), 1703-1711.